Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: The German Biologics JIA Registry

Arthritis and Rheumatology

Volumn 66, Issue 9, 2014, Pages 2580-2589

  Schmeling, Heinrike ^a   Minden, Kirsten ^b   Foeldvari, Ivan ^c   Ganser, Gerd ^d   Hospach, Tony ^e   Horneff, Gerd ^f  

^a UNIVERSITY OF CALGARY   (Canada)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Hamburg Centre for Pediatric and Adolescence Rheumatology   (Germany)

^d Abt Kinder und Jugendrheumatologie   (Germany)

^e OLGAHOSPITAL   (Germany)

^f Department of Paediatrics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADOLESCENT; AGGRESSIVENESS; ALOPECIA; ANXIETY; ARTICLE; CHICKENPOX; CHILD; CONCUSSION; CROHN DISEASE; DEMYELINATING DISEASE; DIABETES MELLITUS; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; EXTERNAL OTITIS; FATIGUE; FEMALE; FEVER; FRACTURE; GASTROENTERITIS; HEADACHE; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INFECTION; INJECTION SITE PAIN; JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE; JUVENILE RHEUMATOID ARTHRITIS; LIVER DISEASE; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA AND VOMITING; NEOPLASM; NEPHRITIS; OPPORTUNISTIC INFECTION; OTITIS MEDIA; PANCREATITIS; PARESTHESIA; PERTUSSIS; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; RASH; REMISSION; SCARLET FEVER; SIDE EFFECT; SINUSITIS; SOFT TISSUE INFECTION; SORE THROAT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UVEITIS; VIRUS INFECTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; BIOLOGICAL PRODUCTS; CHILD; FEMALE; GERMANY; HUMANS; MALE; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84907415657     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38741     Document Type: Article

References (38)

1. Minden K, Niewerth M, Listing J, Zink A, and the German Study Group of Pediatric Rheumatologists. Health care provision in pediatric rheumatology in Germany-national rheumatologic database. J Rheumatol 2002;29:622-8. (Pubitemid 34202837)
2. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
3. Adib N, Silman A, Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis. I. Frequency of different outcomes. Rheumatology (Oxford) 2005;44:995-1001. (Pubitemid 41487171)
4. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84. (Pubitemid 41407360)
5. Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother 2009;10:3049-60.
6. Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003;88:197-200. (Pubitemid 36269497)
7. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al, and the Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group. Methotrexate in resistant juvenile rheumatoid arthritis - results of the USA-USSR double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043-9.
8. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.
9. Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al, for the Pediatric Rheumatology Collaborative Study Group and the Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
10. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al, for the Pediatric Rheumatology Collaborative Study Group. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9. (Pubitemid 30151920)
11. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al, for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504. (Pubitemid 351705939)
12. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al, for the Pediatric Rheumatology Collaborative Study Group. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94. (Pubitemid 43877949)
13. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
14. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al, for the Pediatric Rheumatology Collaborative Group. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44. (Pubitemid 39573695)
15. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford) 2011;50:214-21.
16. Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kummerle-Deschner J, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology (Oxford) 2009;48:916-9.
17. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306:2340-7.
18. Trachana M, Pratsidou-Gertsi P, Pardalos G, Kozeis N, Badouraki M, Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol 2011;40:101-7.
19. Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol 2012;31:1713-21.
20. Katsicas MM, Russo RA. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Clin Rheumatol 2009;28:985-8.
21. Magli A, Forte R, Navarro P, Russo G, Orlando F, Latanza L, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 2013;251:1601-6.
22. Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry [published erratum appears in J Rheumatol 2013;40:106]. J Rheumatol 2013;40:74-9.
23. Kotaniemi K, Saila H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 2011;5:1425-9.
24. Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008;47:339-44. (Pubitemid 351267203)
25. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
26. Foeldvari I, Ruperto N, Dressler F, Hafner R, Kuster RM, Michels H, et al Paediatric Rheumatology International Trials Organisation. The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001;19:S71-5. (Pubitemid 33730191)
27. Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al, for the Paediatric Rheumatology International Trials Organisation. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658-66.
28. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Pediatric Rheumatology Collaborative Study Group (PRCSG), and the Paediatric Rheumatology International Trials Organisation (PRINTO). American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929-36.
29. Horneff G, Foeldvari I, Minden K, Ganser G, Haas JP, Hospach A, et al. Zehn Jahre Erfahrung im deutschen JIA-Etanercept- Register. Z Orthop Rheumatol 2011;31:334-42.
30. Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, et al, on behalf of the British Society for Adolescent and Paediatric Rheumatology Biologics and New Drugs Register. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford) 2011;50:189-95.
31. Otten MH, Prince FH, Anink J, ten Cate R, Hoppenreijs EP, Armbrust W, et al. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis 2013;72:721-7.
32. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 2005;44:1008-11. (Pubitemid 41487173)
33. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91:319-24. (Pubitemid 46586527)
34. Simonini G, Taddio A, Cattalini M, Caputo R, de Libero C, Naviglio S, et al. Prevention of flare recurrences in childhoodrefractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) 2011;63:612-8.
35. Horneff G, de Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al, and the German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
36. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
37. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24.
38. Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, et al, on behalf of the SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum 2012;64:2773-80.